Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Encephalitis Treatment Market

Encephalitis Treatment Market Trends

Report ID: GMI5756
Published Date: May 2023
Report Format: PDF

Download Free Sample

Encephalitis Treatment Market Trends

Encephalitis is a global concern due to its high mortality and morbidity. It is important to treat such diseases in order to overcome the mortality issues all over the globe. According to National Institute of Health, incidences of encephalitis worldwide range from 3.5 to 7.4 per 100,000 patients per year, despite improved treatment options for encephalitis. According to the same studies, among the encephalitis patients, encephalitis leads to death in 5–20% of them. According to the article in the Journal of Infection, in 2019, 1,444,720 incident cases of encephalitis and 89,900 deaths due to encephalitis were estimated.

The growing geriatric population are at high risk of getting infection by viruses which cause encephalitis. Due to the increasing prevalence of encephalitis, pharmaceutical and biotechnology companies have increased their investment in R&D in order to develop new treatment options to treat various types of encephalitis. The surging initiatives by government and private organizations for the treatment of encephalitis will drive the market trends.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for encephalitis treatment was worth USD 20.6 billion in 2022 and is set to exhibit around 4.7% CAGR from 2023 to 2032 attributed to the growing incidence of encephalitis and the rising government initiatives and healthcare expenditure.

The antiviral agent segment is expected to grow exponentially through 2032 owing to its increasing use for treating primary encephalitis due to its widespread availability and cost-effectiveness.

The North America encephalitis treatment market generated the highest revenue in 2022 and is poised to depict robust growth through 2032 on account of massive investments in R&D for developing new drugs for treating encephalitis coupled with the presence of key players.

Pfizer Inc., Merck & Co., Inc., Allergan, GlaxoSmithKline plc, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Sanofi, Teva Pharmaceutical Industries Ltd., Basilea Pharmaceutical Ltd., and Melinta Therapeutics LLC are the major players in the global market.